Sanofi successfully secured the transfer of gosanofi.shop and mysanofi.shop, domains registered by Nikhil Nainwani to divert traffic to third-party sites. The UDRP panel ruled the registrations were made in bad faith to exploit Sanofi’s global pharmaceutical reputation.
Case Snapshot
| Case Number | D2025-5062 |
|---|---|
| Complainant | Sanofi |
| Respondent | Nikhil Nainwani, MagicallyGenius |
| Disputed Domain | gosanofi.shopmysanofi.shop |
| Threat Tactic | Brand Plus Keyword |
| Decision Date | 2026-01-28 |
| Panelist | Reyes Campello Estebaranz |
| Outcome | Transfer |
| Official Source | https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2025-5062 |
Commercial Risk of High-Intent Prefixing and Retail TLD Exploitation
The registration of gosanofi.shop and mysanofi.shop represents a calculated attempt to exploit Sanofi’s global pharmaceutical reputation through high-intent prefixes and retail-centric Top-Level Domains. By combining the SANOFI trademark with action-oriented prefixes like "go" and "my," the respondent created a digital environment that suggests official transactional or personalized services. For a multinational corporation operating in over 180 countries with more than 90,000 employees, this tactic poses a direct threat to consumer trust. Patients or healthcare providers seeking official Sanofi digital storefronts or portals for prescription medicines may be misled into believing these domains are authorized entry points, especially given the total absence of any relationship or disclaimer clarifying the lack of affiliation.
The primary commercial threat in this matter stems from the systematic diversion of internet traffic to third-party websites for the respondent’s commercial gain. The Panel found that the disputed domains were not used for any bona fide offering of goods but were instead utilized to profit from Sanofi’s international reputation and goodwill. This diversion causes tangible harm by diluting the brand’s digital presence and potentially exposing consumers to unverified third-party content under the guise of the Sanofi name. Because Sanofi manages an extensive portfolio of legitimate domains, including sanofi.com, sanofi.eu, and sanofi.fr, the presence of unauthorized .shop sites tarnishes established goodwill and necessitates rapid enforcement. The respondent’s ability to deploy these assets within only eight days of registration underscores the persistent risk of brand-plus-keyword tactics used to capture and monetize redirected user traffic.
Panel Reasoning: Confusing Similarity, Lack of Rights, and Opportunistic Bad Faith
The Panel determined that the disputed domain names, gosanofi.shop and mysanofi.shop, are confusingly similar to the Complainant’s SANOFI trademark. The SANOFI mark is entirely incorporated within the domains, alongside descriptive prefixes ‘go’ and ‘my’. Under established UDRP principles, the addition of such prefixes does not mitigate the likelihood of confusion, as the trademark remains the dominant and recognizable element within the strings. Furthermore, the generic Top-Level Domain (gTLD) ‘.shop’ was disregarded in the assessment, as it is a standard functional component of the Domain Name System and fails to distinguish the domains from the protected pharmaceutical mark.
Regarding rights or legitimate interests, the Panel found that the Respondent, Nikhil Nainwani, lacked any authorization or license to utilize the SANOFI mark. There was no evidence of a prior business relationship between the parties, nor was there any indication that the Respondent was commonly known by the disputed names. The use of the domains to divert internet traffic to third-party websites for commercial gain does not constitute a bona fide offering of goods or services or any legitimate noncommercial activity. This absence of legitimate interest was further reinforced by the Respondent’s failure to provide any evidence of preparations to use the domains for a lawful purpose prior to the dispute.
The finding of bad faith registration and use was predicated on the extensive international reputation and goodwill associated with the SANOFI brand. Given Sanofi’s operation in over 180 countries and its long-standing trademark registrations dating back to at least 2012, the Panel concluded the Respondent likely had actual or at least constructive notice of the mark at the time of registration on November 27, 2025. The targeting of the mark was characterized as ‘opportunistic bad faith’ specifically designed to profit from Sanofi’s established reputation. By misleading users and diverting them to external sites, the Respondent sought to capitalize on the trademark’s value for unauthorized commercial benefit.
This case underscores the specific risks associated with retail-oriented gTLDs like ‘.shop’ when paired with established pharmaceutical brands. The registration of ‘brand + keyword’ domains can lead to immediate brand dilution and the potential for consumer deception regarding the existence of official digital storefronts. Sanofi’s rapid enforcement timeline—filing the UDRP complaint only eight days after the initial domain registrations—demonstrates a proactive defensive strategy necessary to mitigate the impact of traffic diversion. For IP professionals, this highlights that even brief periods of unauthorized use can tarnish global goodwill, requiring vigilant monitoring of new gTLD registrations.
Strategic Rapid Enforcement and Trademark Renown
Sanofi’s success in this proceeding was anchored by a rapid enforcement response, with the UDRP complaint filed only eight days after the unauthorized domain registrations. By leveraging its extensive global footprint—spanning 180 countries and supported by a workforce of 90,000—the Complainant established that its SANOFI trademark possesses a level of international renown that makes claims of coincidental registration implausible. This established reputation was central to the legal finding that the Respondent acted with opportunistic bad faith. The Panelist accepted that the Respondent likely had actual or constructive notice of the pharmaceutical giant’s brand, concluding that the registrations were specifically designed to exploit the goodwill associated with Sanofi’s prior trademark rights, such as EU Reg. No. 010167351.
The Complainant’s strategy also effectively addressed the nuances of ‘brand plus keyword’ tactics within retail-oriented generic Top-Level Domains (gTLDs). By arguing that the prefixes ‘go’ and ‘my’ failed to eliminate confusing similarity, Sanofi focused the Panel’s attention on the wholesale incorporation of its mark. The evidentiary showing that the domains were used to divert traffic to third-party websites for commercial gain was critical in debunking any claims of rights or legitimate interests. Furthermore, the choice of the ‘.shop’ extension underscored a business risk where internet users might expect an official digital storefront, a factor the Complainant used to demonstrate the misleading nature of the Respondent’s activities. This combination of documented trademark strength and clear evidence of traffic diversion for profit ensured a decisive finding of bad faith use.
Practical Recommendations
- Execute rapid-response UDRP filings within 10 days of domain registration to minimize the period of active traffic diversion and prevent the establishment of deep-linked malicious content.
- Configure brand monitoring alerts to specifically target ‘brand + keyword’ combinations using high-conversion prefixes such as ‘go’ and ‘my’ paired with retail-focused gTLDs like ‘.shop’.
- Archive time-stamped screenshots of redirection paths to third-party commercial sites immediately upon detection to establish a clear evidentiary trail of ‘bad faith use’ for commercial gain.
- Prioritize enforcement against unauthorized domains using retail-centric gTLDs that mimic digital storefronts, as these are statistically more likely to mislead consumers into believing an official relationship exists.
- Ensure all UDRP complaints provide detailed evidence of the brand’s global reach and prior trademark registrations to satisfy the ‘constructive notice’ standard for bad faith registration.
Frequently Asked Questions (FAQ)
Why were ‘gosanofi.shop’ and ‘mysanofi.shop’ considered confusingly similar to the SANOFI trademark?
The WIPO panel found that these domains incorporate the SANOFI trademark in its entirety. The addition of the prefixes ‘go’ and ‘my’ fails to eliminate the likelihood of confusion, and the generic Top-Level Domain (gTLD) ‘.shop’ is disregarded in the assessment of confusing similarity.
What evidence proved the respondent lacked rights or legitimate interests in the domain names?
The respondent, Nikhil Nainwani, had no authorization or business relationship with Sanofi. Furthermore, the domain names were not used in connection with any bona fide offering of goods or services, but were instead used to divert internet users to third-party websites.
How did the panel determine that the respondent acted in bad faith?
Given the global reputation of the SANOFI brand, the panel concluded the respondent had constructive or actual notice of the trademark at the time of registration. The respondent targeted the mark with opportunistic intent to profit from Sanofi’s international goodwill and reputation.
What does this case demonstrate regarding the enforcement of pharmaceutical brand protection?
This case highlights the efficacy of a rapid enforcement strategy. By filing the UDRP complaint within eight days of the domain registrations, Sanofi effectively neutralized the threat before the domains could further tarnish its reputation through misleading traffic diversion.
Detecting Brand-Plus-Keyword Impersonation
Abusers are increasingly using ‘go’, ‘my’, and other prefixes to create deceptive ‘brand-plus-keyword’ domains that siphon traffic and dilute your intellectual property. Don’t wait for brand harm to escalate; assess your current domain risk and UDRP eligibility today.
This case note is for informational purposes only and is not legal advice.
